ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 970 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
ANI Pharmaceuticals Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
ANI Pharmaceuticals Incの収益はセグメントまたは地域別にどのように分けられていますか?
ANI Pharmaceuticals Inc の最大収益セグメントは Rare Disease and Brands で、最新の利益発表における収益は 483,933,000 です。地域別に見ると、United States が ANI Pharmaceuticals Inc の主要市場であり、収益は 852,443,000 です。